Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giuseppe Viale, Claudio Zamagni et al.|The Lancet Oncology|2018Cited by 174
Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo studyLorenzo Gianni, G. Viale, Giancarlo Bisagni et al.|Cancer Research|2017Cited by 5